Navigation
banner
Together we Drive the Future

Kinase Inhibitors in Drug Discovery

2017-06-292017-09-162017-08-16
EARLY BIRD DISCOUNT! Register by Aug 16, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


registration button

European Pharma Summit


Kinase Inhibitors in Drug Discovery

GPCR Targeted Screening

Drug Design & Medicinal Chemistry
 
 

Subscribe for updates



Dear Colleague,

GTCbio and the Advisory Board would like to invite you the 3rd Kinase Inhibitors in Drug Discovery Conference. This event takes place November 16-17, 2017 in Berlin, Germany and is one of 3 co-located conferences at the European Pharma Summit.

This meeting brings together industry leaders from major pharmaceuticals, biotech companies, and top researchers from academia to provide a timely and critical summary to update significant kinase inhibitors and better understand current trends for drug design and the screening processes. Register for this event to hear recent developments in allosteric kinase inhibitors, covalent inhibitor strategies, irreversible and RAF inhibitors, mechanisms of kinase inhibitor resistance, and mutation-focused approaches towards kinase inhibition.

Session topics:

  1. Opening Plenary: Chemical Biology for Target Identification and Validation
  2. Technological Advances for Studying the Kinome
  3. Kinase Inhibitor Design
  4. Optimizing Target Residence Times in Kinase Drug Development
  5. Overcoming Therapeutic Resistance
  6. Closing Plenary: Hot Topics in Drug Discovery for the Future

We hope to see you there!


Best regards,

The 2017 Advisory Committee

2017 Advisory Board Members
David Litchfield, Western University
Pedro Cutillas, Barts Cancer Institute
Stefan Knapp, University of Oxford
Joshua Salafsky, Biodesy Inc.
Doriano Fabbro, PIQUR Therapeutics
Gerhard Mueller, Mercachem BV
Ricardo Biondi, Frankfurt University Hospital
Michael Burnet, Synovo GmbH
Angus Cameron, Barts Cancer Institute
Hicham Alaoui, Genentech
Henrik Moebitz, Novartis
Alexei Degterev, Tufts University